newest glp-1 drug Agonists: A Comprehensive Overview List of approved and pending

In this randomized, double-blind, placebo-controlled, 3-week crossover trial, 34 patients with primary polydipsia received weekly dulaglutide (1.5 mg, Trulicity) in one treatment segment and placebo (0.9% sodium chloride) in the other

The LEADER-6 study shown substantial cardiovascular advantages of liraglutide in high-risk patients, while SUSTAIN-6 revealed a significant decrease in cardiovascular event-related mortality with subcutaneous semaglutide (Verma et al

(2021a)

They said: By the end of 2023, we will have dedicated more than $5 billion USD to open new production lines and facilities

Animal data on a GLP-1/GIP/glucagon triple agonist show strong effects on body weight reduction, and glucose- and lipid normalization in rodents

Yet current prescribing guidelines dont recommend asking a basic question before initiating treatment: Does this patient actually have low endogenous GLP-1 levels